High risk NSGCT: case for surveillance
| 详细信息 | 推荐本文 | |
- 作者：David Michael Kakiashvili ; Alvaro Zuniga and Michael A. S. Jewett
- 关键词：Testis cancer ; Nonseminoma ; Stage I ; Active surveillance
- 刊名：World Journal of Urology
- 出版时间：August, 2009
- 出版年：2009
- 期刊代码：220_0724-4983
- 类别：med
- 卷：27
- 期：4
- 页码：441-447
- 数据来源：sp
摘要
Introduction Active surveillance, primary retroperitoneal lymph node dissection and adjuvant chemotherapy are treatment options for high-risk clinical stage (CS) I nonseminomatous germ cell testicular tumors (NSGCT). Since 1981, at Princess Margaret Hospital, Toronto, initial active surveillance with treatment delayed until relapse has been the preferred management option for all CS I NSGCT, regardless of baseline risk of relapse which has allowed us to better define and assess the natural history of high-risk tumors.